Fresenius Medical Care

Ronin Announces Three Hires as Part of an Ongoing Expansion of Firm Resources

Retrieved on: 
Monday, September 26, 2022

Before joining Ronin, Clavon was a Strategy Manager on the Supply Chain Finance team at Campbells Soup in the Snacks division.

Key Points: 
  • Before joining Ronin, Clavon was a Strategy Manager on the Supply Chain Finance team at Campbells Soup in the Snacks division.
  • Like all Ronin executives, he will periodically rotate into senior operational roles at portfolio companies.
  • Ronins ongoing recruitment program includes three more hires planned for later this year (last Octobers hiring of Associate Elliott Rogasik formerly at BlackRock - kicked off the expansion program).
  • Based in New York City, Ronin Equity Partners represents a new type of investment firm, powered by an operationally-focused value creation strategy.

EQS-News: How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Retrieved on: 
Friday, September 23, 2022

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.

Key Points: 
  • Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.
  • In fact, each year, more people die from this silent killer than from breast or prostate cancer.
  • Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting

Retrieved on: 
Friday, September 23, 2022

Trauma to the extremities makes up the majority of injuries, primarily vascular injuries to the lower extremities and shoulders.

Key Points: 
  • Trauma to the extremities makes up the majority of injuries, primarily vascular injuries to the lower extremities and shoulders.
  • Shaprynskyi and Sokolov reported that surgeons in Ukraine have utilized the HAV to treat patients with a multitude of wartime injuries.
  • The HAV has received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.

Global End Stage Renal Disease Market Report (2022 to 2030) - Growing Prevalence of Diabetes and Hypertension is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022

The global end stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 12.9% over the forecast period.

Key Points: 
  • The global end stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 12.9% over the forecast period.
  • Chronic Kidney Disease (CKD) is one of the major causes of increasing kidney failure rates among patients.
  • Technological advancements in the treatment of renal failure are another factor expediting the market growth for ESRD.
  • End Stage Renal Disease Market Variables, Trends & Scope

Quickbase and Procore Partner to Help Fuel Business-led Innovation for Unique Workflows

Retrieved on: 
Wednesday, September 14, 2022

The partnership empowers Procore users with a powerful no-code toolkit to create unique, real-time applications to enhance workflows and unlock new possibilities within Procore, all without the need of professional developers.

Key Points: 
  • The partnership empowers Procore users with a powerful no-code toolkit to create unique, real-time applications to enhance workflows and unlock new possibilities within Procore, all without the need of professional developers.
  • "The business innovators already using Quickbase and Procore, including Consigli Construction and Fresenius Medical, can now create real-time applications tailored to their unique business requirements, said Ed Jennings, CEO of Quickbase.
  • This drag-and-drop integration builds off of Quickbases existing API integrations long used by Procore customers, and is available today to Quickbase existing customers.
  • The integration with Quickbase empowers Procore users to create applications and solutions for their unique business challenges and help ensure they can handle that complexity and get their jobs done successfully.

USOSM Recruits Robert Manning as Vice President of Business Development

Retrieved on: 
Tuesday, September 13, 2022

IRVING, Texas, Sept. 13, 2022 /PRNewswire-PRWeb/ -- U.S. Oral Surgery Management (USOSM) – a specialty management services company that exclusively serves premier oral and maxillofacial surgeons – has named healthcare industry veteran Robert Manning as a vice president of business development. In his new position, Manning will be responsible for the strategic growth and development of USOSM by seeking out new surgeon partners and ensuring a smooth transition during the partnership process.

Key Points: 
  • Oral Surgery Management (USOSM) has named healthcare industry veteran Robert Manning as a vice president of business development.
  • Oral Surgery Management ( USOSM) a specialty management services company that exclusively serves premier oral and maxillofacial surgeons has named healthcare industry veteran Robert Manning as a vice president of business development.
  • "We're excited to announce Robert Manning has joined USOSM as a vice president of business development," said Richard Hall, USOSM president and CEO.
  • Before that, Manning served as vice president of business development at Mednax Inc.

Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress

Retrieved on: 
Friday, September 9, 2022

USAF MC), at the 44th International Committee of Military Medicine (ICMM) World Congress in Brussels, Belgium.

Key Points: 
  • USAF MC), at the 44th International Committee of Military Medicine (ICMM) World Congress in Brussels, Belgium.
  • Dr. Rasmussen added that vascular injury, whether in a military or civilian setting, is a leading cause of death and or amputation.
  • The incidence of vascular trauma in the modern combat setting has increased 5-fold over the past century.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.

Fresenius Medical Care partners with National Kidney Foundation Malaysia in kidney health initiative

Retrieved on: 
Wednesday, September 7, 2022

Fresenius Medical Care, the worlds leading provider of products and services for individuals with renal diseases, today signed a memorandum of understanding (MoU) with the National Kidney Foundation (NKF) Malaysia, to work together in promoting kidney health and the prevention of chronic kidney disease amongst children and their families in Malaysia.

Key Points: 
  • Fresenius Medical Care, the worlds leading provider of products and services for individuals with renal diseases, today signed a memorandum of understanding (MoU) with the National Kidney Foundation (NKF) Malaysia, to work together in promoting kidney health and the prevention of chronic kidney disease amongst children and their families in Malaysia.
  • The organizations will leverage Fresenius Medical Cares international Corporate Social Responsibility (CSR) initiative, The Kidney Kid, to provide education and entertainment about kidney health to children and their carers.
  • View the full release here: https://www.businesswire.com/news/home/20220907005686/en/
    Fresenius Medical Care today signed a memorandum of understanding (MoU) with the National Kidney Foundation Malaysia, to work together in promoting kidney health and the prevention of chronic kidney disease amongst children and their families in Malaysia.
  • The Kidney Kid represents Fresenius Medical Cares commitment to building awareness of kidney health and assisting prevention of CKD in the diverse communities we serve.

Global Hemodialysis and Peritoneal Dialysis Market Analysis/Forecast 2022-2028: Market Strategies by Key Players & Shift in Preference of Patients for Home Care Dialysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 31, 2022

The presence of competitive market players introducing advanced products and services with innovative strategies acts as a future trend of the hemodialysis and peritoneal dialysis market.

Key Points: 
  • The presence of competitive market players introducing advanced products and services with innovative strategies acts as a future trend of the hemodialysis and peritoneal dialysis market.
  • The global hemodialysis and peritoneal dialysis market is segmented on the basis of type, product, and end user.
  • Additionally, the Regents of the University of California report states that various health centers offer quality hemodialysis and peritoneal dialysis services.
  • Such aforementioned factors would highly support the growth of the hemodialysis and peritoneal dialysis market during the forecast period.

CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy

Retrieved on: 
Monday, August 22, 2022

The EMA will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the second half of 2023.

Key Points: 
  • The EMA will review the application under the centralized marketing authorization procedure and a review decision on a potential approval is expected in the second half of 2023.
  • We look forward to continuing to collaborate with our partners at CSL Vifor and with the EMA throughout the review process.
  • Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
  • There is no guarantee that the EMA will grant conditional marketing authorization of sparsentan for IgAN or that sparsentan will be approved at all.